Slovenia has temporarily suspended the use of Johnson & Johnson's (NYSE:JNJ) COVID-19 vaccines after the death of a young woman, Reuters news agency reported on Wednesday, citing the STA national news agency.
STA reported that the patient had blood clots and bleeding in the brain at the same time and intensive care was not successful.
Health minister Janez Poklukar said he was not familiar with the details of the case.
"I can't make comments, but the conditions have been met for clarifying all the circumstances of what happened," he said.
The J&J Janssen COVID-19 vaccine is one of the several vaccines Slovenia is using in its vaccination programme.
Valneva reports positive final Phase 2 results for Lyme disease vaccine VLA15
Lunai Bioworks receives first LOI to license next-generation immune cell therapy
BioNet receives positive opinion from EMA for VacPertagen marketing authorisation in EU
Anixa Biosciences secures U.S. Patent strengthening breast cancer vaccine IP into mid 2040s
PharmaJet® and EVA Pharma Partner to Scale Needle-free Polio Immunisation Across Egypt
Frontier IP portfolio company achieves breakthrough in livestock vaccine trials
GC Biopharma's Phase 2 clinical trial results for BARYTHRAX published in Vaccine
Bavarian Nordic secures new EU contract for up to 8 million smallpox and mpox vaccine doses
Zoetis announces EU approval for Portela to relieve osteoarthritis pain in cats
4basebio synthetic DNA used in Phase I/II mRNA therapy trial
Arcturus reports interim Phase 2 data for ARCT-032 in cystic fibrosis
Sanofi reports data showing high-dose flu vaccine delivers superior protection for older adults
GC Biopharma granted CMO rights for Curevo Vaccine's shingles vaccine